Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
HLA-F Biologics Sequence Review Report 2026: HLA class I histocompatibility antigen, alpha chain F Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of HLA-F protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
HLA-DRB5 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DR beta 5 chain Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of HLA-DRB5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
HLA-DQA2 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DQ alpha 2 chain Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of HLA-DQA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
HLA-DRA Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DR alpha chain Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of HLA-DRA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPRC5D Biologics Sequence Review Report 2026: G protein-coupled receptor family C group 5 member D Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPRC5D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
HLA-DRB1 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DRB1 beta chain Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of HLA-DRB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
HLA-DQB2 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DQ beta 2 chain Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of HLA-DQB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
HLA-DRB3 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DR beta 3 chain Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of HLA-DRB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPRC5C Biologics Sequence Review Report 2026: G protein-coupled receptor family C group 5 member C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPRC5C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
HLA-DQB1 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DQ beta 1 chain Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of HLA-DQB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR87 Biologics Sequence Review Report 2026: G protein-coupled receptor 87 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR87 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPRC5B Biologics Sequence Review Report 2026: G protein-coupled receptor family C group 5 member B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPRC5B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.